Radiotherapy in indolent gastroduodenal lymphoma patients tied to diabetes: Study
Seoul, Korea: Patients with gastroduodenal indolent lymphoma who receive radiotherapy (RT) are at increased diabetes risk compared to those who do not, finds a recent study in the journal Cancer Research and Treatment.
Jong Yun Baek, Sungkyunkwan University School of Medicine, Seoul, Korea, and colleagues aimed to evaluate the effect of radiotherapy on the risk of diabetes by assessing hemoglobin A1c (HbA1c) levels in gastroduodenal indolent lymphoma patients.
For this purpose, the researchers performed a retrospective study that included patients with stage I extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue or follicular lymphoma of the gastroduodenal region. They were treated with Helicobacter pylori eradication and/or RT between 2000 and 2019 in our institution.
Of the total 79 patients with HbA1c test, 17 patients received RT (RT group), while 62 patients did not receive RT (Control group). A Diabetes-associated event (DAE) was defined as a ≥ 0.5% increase in HbA1c levels from baseline, and diabetes events (DE) were defined as an HbA1c level of ≥ 6.5%.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.